Harmony Biosciences is trading at $36.66, down 4.11%, as the pullback following its CEO succession announcement continues. - CEO Jeffrey Dayno will retire at year-end; COO Peter Anastasiou will succeed him on January 1, 2027. - A market report linked the previous session’s selloff to the leadership announcement. - The biotech sector is also lower, though the leadership transition is the clearest identified company-specific catalyst.